In osteoarthritis, inflammatory bowel disease, and psoriasis, PGRN can effectively inhibit the inflammatory signaling pathway mediated by TNF-α and reduce the expression of downstream inflammatory factors, thus inhibiting the inflammatory response mediated by TNF-α18. The gene discussed is TNF; the disease is osteoarthritis.